Search for whether a peptide is legal and most answers come in one word. The documents are more specific, and they differ peptide by peptide. This page sorts every peptide with an entry on this site into what FDA and HHS have written about it, and links the document behind each status.
Ask PeptideBlog about any peptide
Quick answer: The formal list of bulk ingredients pharmacies may compound from holds six substances, and none is a peptide.[11] In 2026 FDA took BPC-157 and other peptides off its Category 2 safety list, an advisory committee backed six of seven peptides in July, and on October 30 HHS published a draft policy saying it does not intend to enforce against qualifying compounders of six peptides.[3][4][5] None of that is an approval or a bulks-list listing.
This page documents what regulators have done and said. It is educational reference, not legal or medical advice, and inclusion of a peptide does not mean it is safe, effective or suitable for anyone. The FDA pages, Federal Register notices and HHS documents behind it were checked on 2 November 2026.

What the 503A bulks list and Categories 1, 2 and 3 are
Section 503A of the federal food and drug law lets a state-licensed pharmacist or a physician compound a medicine for one identified patient, from a prescription, without FDA approval of that product.[4] Because the pharmacist starts from raw ingredients, called bulk drug substances, the law limits which ingredients can be used. A bulk substance must meet one of three tests: it has a United States Pharmacopeia or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on a list FDA creates by regulation.[1][4]
The unapproved research peptides in the news, such as BPC-157 and TB-500, have no monograph and are not components of approved drugs, so the list is their only formal route.[34][4] The list is in 21 CFR 216.23. As of the regulation text current on 22 October 2026 it names six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. None is a peptide.[11]
Adding a substance to that list takes rulemaking: a proposal, public comment and a final rule. While that is pending, FDA runs an interim policy that sorts substances nominated for the list into three categories.[1] The categories describe how FDA says it will treat compounders, and they are not a legal list.
Swipe the table sideways to see every column.
| Category | FDA heading or description | What FDA says about enforcement | Peptide and amino-acid entries on FDA’s list today |
|---|---|---|---|
| Category 1 | Bulk Drug Substances Under Evaluation. These may be eligible for the 503A bulks list.[1] | FDA does not intend to take action against a compounder using a Category 1 substance if the conditions in its interim guidance are met.[1] | GHK-Cu (except injectable routes), vasoactive intestinal peptide, glutathione, alanyl-L-glutamine, along with non-peptides such as NAD and methylcobalamin.[2] |
| Category 2 | Bulk Drug Substances That Raise Significant Safety Risks. FDA has identified significant safety risks for compounding with them.[1] | FDA says it would consider taking action against a compounder under its general enforcement policies.[1][3] | The 503A Category 2 list names six substances. Two are peptide-related: kisspeptin-10 and ibutamoren mesylate (MK-677). For 503B outsourcing facilities, GHRP-2, GHRP-6 and ipamorelin acetate are also in Category 2.[3][2] |
| Category 3 | Bulk Drug Substances Nominated Without Adequate Support. The nomination did not give FDA enough information to evaluate the substance.[1] | Not eligible for the Category 1 policy. FDA says it would consider taking action under its general policies. Substances can be nominated again.[1] | GHRP-2, GHRP-6, mechano growth factor (MGF), cibinetide (ARA-290), thymulin acetate, human secretin and L-carnosine.[2] |
| No category | Substances nominated on or after January 7, 2025, which FDA says it does not intend to place in categories, and nominations that were withdrawn.[1][2] | No category policy applies. The general rules for 503A ingredients apply.[1] | BPC-157, TB-500, KPV, MOTS-c, Semax, epitalon, CJC-1295, ipamorelin (503A), AOD-9604, thymosin alpha-1, selank, melanotan II, LL-37, dihexa and others, all listed by FDA as nominations withdrawn from Category 2.[3] |
FDA’s Category 1, 2 and 3 lists carry a 14 May 2026 revision date and its Category 2 safety page a 22 April 2026 date. This page does not print the total number of entries in each category, because the counts could not be read directly from a document and FDA updates the lists.
Four things that get mixed up
- Leaving Category 2 is not entering Category 1. HHS’s own document says neither the placement of the six peptides in Category 2 nor their removal changed their status under section 503A.[4] FDA’s Category 1 policy applies only to Category 1 substances.[1]
- An advisory committee vote is advice to FDA. Putting a substance on the bulks list requires a rule.[1][4]
- Enforcement discretion is an agency saying it does not intend to enforce in described circumstances. The HHS notice says its policy does not establish rights for anyone, is not binding on HHS or the public, and may be revisited if a safety signal or product quality problem appears.[5][4]
- HHS’s Appendix A, which it calls the 503A Interim Access List, is a separate device from the three categories. A peptide can be on Appendix A without being in Category 1.[4]
Timeline of the 2026 actions
Most of the confusion online comes from dates running together. The table separates what happened from who documented it. Rows cited to FDA, HHS, the Federal Register or a legislature are primary documents. Rows marked reported rest on law-firm or trade coverage, because no government document for that step was found.
Swipe the table sideways to see every column.
| Date | What happened | Basis |
|---|---|---|
| February 2019 | FDA’s final rule placed six substances on the 503A bulks list. None is a peptide.[1][11] | Primary: FDA, regulation |
| September 2023 | BPC-157 and KPV were in Category 2 from September 2023. TB-500, epitalon, Semax and MOTS-c were in Category 2 from September 29, 2023.[4] On September 29, 2023 FDA also placed kisspeptin-10 and ibutamoren (503A), and GHRP-2, GHRP-6 and ipamorelin acetate (503B), in Category 2.[3] | Primary: HHS and FDA |
| October 29, 2024 | The advisory committee (PCAC) voted against placing ipamorelin, kisspeptin-10 and ibutamoren mesylate on the bulks list. L-theanine, not a peptide, was voted down at the same meeting.[10] | Primary: FDA minutes |
| December 4, 2024 | PCAC voted against placing CJC-1295, AOD-9604 and thymosin alpha-1 on the bulks list.[9] | Primary: FDA minutes |
| January 2025 | FDA’s revised interim policy says it does not intend to place substances nominated on or after January 7, 2025 into the categories.[1] | Primary: FDA page |
| February 6, 2026 | FDA announced it intends to restrict GLP-1 active ingredients used in non-approved compounded drugs and to act on claims that compounded products are generic versions of, or the same as, approved drugs.[13] | Primary: FDA press release |
| February 27, 2026 | HHS Secretary Robert F. Kennedy Jr. said on a podcast that FDA action making about 14 peptides more accessible was expected. No HHS or FDA press release dated that day was found.[32] | Reported: law-firm analysis of the remarks |
| April 15 to 16, 2026 | FDA announced it would remove twelve peptides from Category 2 within seven calendar days because the nominators had withdrawn their nominations.[31] FDA’s Federal Register notice of the July committee meeting (91 FR 20465) was published April 16.[7] | Reported (15 April announcement); primary (16 April notice) |
| April 22, 2026 | HHS records that BPC-157, KPV, TB-500, epitalon, Semax and MOTS-c were removed from Category 2 on this date.[4] FDA’s Category 2 page, current as of April 22, lists 17 nominations as withdrawn by the nominators, including all of those and others.[3] | Primary: HHS and FDA |
| May 5 to 14, 2026 | A nominator clarified that it withdrew only the injectable-route nomination for GHK-Cu. FDA added GHK-Cu (except injectable routes) back to Category 1 and said it intends to consult the committee before the end of February 2027.[2] | Primary: FDA list |
| Late June 2026 | FDA was reported to have added eight temporary members to the committee, which one trade newsletter described as then having 43 members.[36] | Reported: trade association newsletter |
| July 23 and 24, 2026 | PCAC met on seven substances: BPC-157, KPV, TB-500 and MOTS-c on July 23; emideltide (DSIP), Semax and epitalon on July 24.[6][7] FDA’s staff briefing proposed that none of the 14 forms (free base and acetate of each) be included.[8] HHS later recorded that the committee voted in favor of including six of them, against its drug center’s recommendation.[4] Trade press reports emideltide as the one the committee did not recommend.[29][28][30] | Primary: FDA and HHS; reported for emideltide |
| August 24, 2026 | FDA issued a warning letter to an online seller of retatrutide, semaglutide, tesamorelin, SS-31 and PT-141, saying “research use only” labels did not change its conclusion that the products were intended for human use.[14] A law-firm review counts five letters that day.[35] | Primary: one letter read; reported: the count of five |
| October 1, 2026 | FDA updated its page on unapproved GLP-1 drugs, stating that retatrutide and cagrilintide cannot be used in compounding under federal law.[12] | Primary: FDA page |
| October 28 to 30, 2026 | HHS’s enforcement-discretion notice for six peptides was filed for public inspection on October 28 and published in the Federal Register on October 30 (document 2026-22192, docket HHS-OASH-2026-0496).[5] | Primary: Federal Register |
| November 13, 2026 | Public comments are due, two weeks after publication.[5][34] | Primary: notice text; date per law-firm analysis |
| Before the end of February 2027 | FDA says it intends to consult the committee on GHK-Cu. Law-firm and trade reports say four more peptides (LL-37, dihexa, melanotan II and pegylated MGF) are scheduled for the same meeting.[2][38] | Primary for GHK-Cu; reported for the rest |
On the July vote counts: trade outlets print different tallies for the same votes (epitalon and MOTS-c in particular), and FDA’s meeting page had no minutes or voting results when checked. The outcomes below come from HHS’s own document. Counts are left out here because none could be read in a primary document.
Status of each peptide, in one table
The table covers the entries on this site that appear on an FDA list or in one of these actions, grouped by where they sit. Names link to the entry page. The right-hand column links the document the status comes from. A peptide missing from a list has no status on that list, and that is not a permission. Peptides with no mention in any of the documents read are not listed.
Swipe the table sideways to see every column.
| Peptide | FDA or HHS status as verified | What that means | Source |
|---|---|---|---|
| 1. On HHS’s October 2026 enforcement-discretion list (Appendix A) | |||
| For all six: not FDA-approved, not on the 503A bulks list, in Category 2 until April 22, 2026, and recommended by the advisory committee in July 2026 while FDA’s drug center recommended against.[4][5] Each is covered only in the exact form and route in Appendix B, and only under ten conditions including a patient-specific prescription and a single active ingredient per product. | |||
| BPC-157 | Appendix A lists BPC-157 acetate for subcutaneous, intramuscular, oral and topical use.[4] Committee agenda: July 23, 2026, ulcerative colitis as the use evaluated.[7] | HHS says it does not intend to take enforcement action against a qualifying 503A pharmacy, federal facility or licensed physician compounding this acetate by those routes, until a final rule addresses it. Oral products need documented human oral bioavailability. Other salts and routes sit outside the notice.[4] | HHS policy PDF FDA meeting page |
| TB-500 and thymosin beta-4 | Appendix A lists TB-500 acetate, defined as the seven-amino-acid sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, for subcutaneous or intramuscular injection.[4] FDA’s Category 2 page names it as the thymosin beta-4 fragment (LKKTETQ), also known as TB-500.[3] Use evaluated: wound healing.[7] | The listing covers the acetylated fragment. Full-length thymosin beta-4 is a different substance that does not appear in Appendix A.[4] | HHS policy PDF FDA Category 2 page |
| KPV | Appendix A lists KPV acetate for topical and oral use only. Subcutaneous use is not listed.[4] Use evaluated: wound healing and inflammatory conditions.[7] | Cover applies to the topical and oral forms. An injectable KPV product has no cover under the notice. HHS’s stated rationale for KPV does not discuss the route list.[4] | HHS policy PDF FDA meeting page |
| MOTS-c | Appendix A lists MOTS-c acetate for subcutaneous or intramuscular injection.[4] Uses evaluated: obesity and osteoporosis.[7] | HHS notes that its safety reasoning draws on a placebo-controlled trial of an analogue of MOTS-c, which is a different molecule.[4] | HHS policy PDF FDA meeting page |
| Semax | Appendix A lists Semax free base for intranasal use only.[4] Uses evaluated: cerebral ischemia, migraine and trigeminal neuralgia.[7] | The listing is tied to the intranasal route and to the free base. HHS cites intranasal human data on several hundred subjects with no reported adverse outcome.[4] An injected or acetate form falls outside the identity Appendix B describes. | HHS policy PDF FDA meeting page |
| Epitalon (epithalon) | Appendix A lists epitalon acetate for subcutaneous or intramuscular injection, dispensed in intermittent courses.[4] FDA and HHS use the spelling epitalon. Use evaluated: insomnia.[7] | The intermittent-course limit is part of the listing, so a continuous-use product is outside it.[4] | HHS policy PDF FDA meeting page |
| 2. Reviewed by the committee, but not on HHS’s list | |||
| Emideltide (DSIP) | Reviewed July 24, 2026 for opioid withdrawal, chronic insomnia and narcolepsy.[7] Trade press reports it as the one peptide the committee did not recommend.[29][28][30] It is not among the six in Appendix A.[4] FDA lists it among nominations withdrawn from Category 2.[3] | No enforcement-discretion cover from the October notice, and not on the bulks list. No category applies. | FDA meeting page HHS policy PDF FDA Category 2 page |
| 3. Nominations withdrawn from Category 2, waiting for committee review | |||
| FDA’s own pages confirm the withdrawn-nomination status and, for GHK-Cu, the plan to consult the committee. Law-firm and trade reports say LL-37, dihexa, melanotan II and pegylated MGF (no entry on this site) are slated for the same meeting before the end of February 2027. No FDA page naming those four was found.[3][2][38][31] | |||
| GHK-Cu (also GHK) | Two statuses. GHK-Cu except for injectable routes is in Category 1 on FDA’s list updated May 14, 2026. Injectable GHK-Cu is among the nominations withdrawn from Category 2. FDA says it intends to consult the committee before the end of February 2027.[2][3] | Non-injectable GHK-Cu sits where Category 1 substances sit: under evaluation, with FDA’s interim enforcement policy applying if its conditions are met.[1] Injectable GHK-Cu is not covered by that policy and not in HHS’s Appendix A. | FDA category lists FDA Category 2 page |
| LL-37 (cathelicidin) | Listed by FDA among nominations withdrawn from Category 2.[3] Reported as awaiting committee review before the end of February 2027. | Not on the bulks list, not in Appendix A and in no category. | FDA Category 2 page DLA Piper analysis |
| Dihexa | Listed by FDA among nominations withdrawn from Category 2 (dihexa acetate).[3] Reported as awaiting committee review. | Not on the bulks list, not in Appendix A and in no category. | FDA Category 2 page DLA Piper analysis |
| Melanotan II | Listed by FDA among nominations withdrawn from Category 2.[3] Reported as awaiting committee review. | Not on the bulks list, not in Appendix A and in no category. | FDA Category 2 page DLA Piper analysis |
| 4. Withdrawn from Category 2 and voted down by the committee in 2024, or never reviewed | |||
| CJC-1295 without DAC and with DAC | Listed by FDA among nominations withdrawn from Category 2.[3] On December 4, 2024 the committee voted against placing any of the five forms reviewed (free base and acetate, and three DAC forms) on the bulks list.[9] | Not on the bulks list, not in Appendix A and in no category. The committee vote was advice and FDA has not adopted or reversed it in the documents read. | FDA minutes, Dec 4 2024 FDA Category 2 page |
| Ipamorelin | Listed among nominations withdrawn from Category 2, while ipamorelin acetate remains a Category 2 entry for 503B outsourcing facilities, added September 29, 2023.[3] On October 29, 2024 the committee voted against listing ipamorelin free base and acetate.[10] | Not on the bulks list or in Appendix A. The 503B Category 2 entry remains on FDA’s page. | FDA minutes, Oct 29 2024 FDA Category 2 page |
| AOD-9604 | Listed among nominations withdrawn from Category 2.[3] On December 4, 2024 the committee voted against placing AOD-9604 free base and acetate on the bulks list.[9] | Not on the bulks list, not in Appendix A and in no category. | FDA minutes, Dec 4 2024 FDA Category 2 page |
| Thymosin alpha-1 | Listed among nominations withdrawn from Category 2.[3] On December 4, 2024 the committee voted against placing the free base and acetate on the bulks list.[9] | Not on the bulks list, not in Appendix A and in no category. | FDA minutes, Dec 4 2024 FDA Category 2 page |
| Selank | Listed among nominations withdrawn from Category 2 (selank acetate, TP-7).[3] No committee review of selank was found. | Not on the bulks list, not in Appendix A and in no category. | FDA Category 2 page |
| 5. Still named in a category | |||
| Kisspeptin-10 | Category 2 for 503A since September 29, 2023.[3][2] On October 29, 2024 the committee voted against listing it; the use evaluated was secondary hypogonadism in men.[10] | FDA says it has identified significant safety risks and would consider taking action against a compounder under its general policies.[1] | FDA category lists FDA minutes, Oct 29 2024 |
| MK-677 (ibutamoren mesylate) | Category 2 for 503A since September 29, 2023 and for 503B since December 29, 2022.[3] On October 29, 2024 the committee voted against listing it.[10] | Same Category 2 meaning as above, for both pharmacies and outsourcing facilities. | FDA Category 2 page FDA minutes, Oct 29 2024 |
| GHRP-2 | 503A: Category 3. 503B: Category 2 for injectable and nasal routes since September 29, 2023.[2][3] | Category 3 means the nomination lacked adequate support. The 503B Category 2 entry means FDA has identified significant safety risks for outsourcing facilities. | FDA category lists FDA Category 2 page |
| GHRP-6 | 503A: Category 3. 503B: Category 2 since September 29, 2023.[2][3] | Same as GHRP-2, without a route limit on the 503B entry. | FDA category lists FDA Category 2 page |
| ARA-290 (cibinetide) and thymulin | Category 3: cibinetide (ARA-290) and thymulin acetate are both on FDA’s Category 3 list.[2] | Nominated without adequate support. Not eligible for the Category 1 policy. | FDA category lists |
| 6. Category 1 entries this site also covers | |||
| Category 1 means a substance is under evaluation for the bulks list. FDA says it does not intend to take action against a compounder using one if the conditions in its interim guidance are met.[1] It is not an endorsement of any product. | |||
| Glutathione | Category 1.[2] | Under evaluation for the bulks list. | FDA category lists |
| Vasoactive intestinal peptide (VIP) | Category 1.[2] | Under evaluation for the bulks list. | FDA category lists |
| NAD+ and methylcobalamin | Category 1: nicotinamide adenine dinucleotide (NAD) and methylcobalamin. Neither is a peptide.[2] | Under evaluation for the bulks list. | FDA category lists |
| 7. FDA-approved drugs | |||
| An approved drug is a specific product with an FDA-approved label. A compounded version, or a vial sold under the same ingredient name, is not that product.[15] | |||
| Tesamorelin | Approved as Egrifta products, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (label revised March 2025).[21] Named in the August 24, 2026 warning letter about a seller’s products.[14] | Approval covers the Egrifta products and that labeled use. Tesamorelin does not appear in the FDA category lists read for this page. | Egrifta label FDA warning letter |
| Sermorelin | Geref (sermorelin acetate) injection was an FDA-approved product. FDA determined in 2013 that it was not withdrawn from sale for reasons of safety or effectiveness; its maker discontinued it.[27] Sermorelin does not appear in the FDA category lists read for this page. | Whether a pharmacy may compound from sermorelin acetate under the approved-drug-component test is not answered on any FDA page read for this page, so it is not stated here. | Geref determination |
| Semaglutide | Approved, with initial U.S. approval in 2017 (Wegovy label revised February 2026).[22] FDA states compounded versions are not FDA-approved and that it is not aware of a lawful basis for compounding with semaglutide sodium or semaglutide acetate.[12] FDA announced on February 6, 2026 that it intends to restrict GLP-1 active ingredients used in non-approved compounded drugs.[13] | Brand drugs exist. Compounded products are a separate category that FDA says it has not reviewed. See the Atlas explainers on compounded versus brand and semaglutide. | Wegovy label FDA GLP-1 page FDA press release, Feb 6 2026 |
| Tirzepatide | Approved, with initial U.S. approval in 2022 (Zepbound label revised April 2026).[23] FDA states compounded versions are not FDA-approved.[12] | Brand drugs exist. Compounded versions are not FDA-reviewed. See tirzepatide on the Atlas. | Zepbound label FDA GLP-1 page |
| Liraglutide | Approved, with initial U.S. approval in 2010 (Saxenda for weight management, Victoza for type 2 diabetes).[24] FDA’s October 1, 2026 page does not address liraglutide.[12] | Compounding status of liraglutide was not found in the FDA documents read, so it is not stated here. See liraglutide on the Atlas. | Saxenda label FDA GLP-1 page |
| PT-141 (bremelanotide) | Bremelanotide was approved as Vyleesi on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder.[26] PT-141 is named in the August 24, 2026 warning letter about a seller’s products.[14] | The approved product is Vyleesi for that use. Research-labeled vials are not that product. | Vyleesi approval letter FDA warning letter |
| SS-31 (elamipretide) | Approved as Forzinity under accelerated approval on September 19, 2025, for Barth syndrome in patients weighing 30 kg or more.[25] SS-31 is named in the August 24, 2026 warning letter about a seller’s products.[14] | Approval covers Forzinity for that condition and population. | FDA Forzinity release FDA warning letter |
| 8. Not approved, and FDA says it cannot be compounded or has warned about sales | |||
| Retatrutide | Not approved. FDA says retatrutide cannot be used in compounding under federal law, is not a component of an FDA-approved drug and has not been found safe and effective for any condition.[12] Named in the August 24, 2026 warning letter.[14] | FDA also lists telehealth marketing, active-ingredient distributors and outsourcing-facility repackaging of retatrutide among its concerns. See retatrutide on the Atlas. | FDA GLP-1 page FDA warning letter |
| Cagrilintide | Not approved. FDA says cagrilintide cannot be used in compounding under federal law and is not a component of an FDA-approved drug.[12] | Same statement as retatrutide. See cagrilintide on the Atlas. | FDA GLP-1 page |
| Survodutide and mazdutide | FDA has warned companies that sold unapproved products containing survodutide or mazdutide, labeled for research purposes or not for human consumption but sold directly to consumers with dosing instructions.[12] | FDA’s page urges consumers not to buy such products. It does not make a separate compounding statement for these two. | FDA GLP-1 page |
| 9. No status found in the documents read | |||
| Hexarelin | Not named in FDA’s Category 1, 2 or 3 lists, its Category 2 page, the committee materials or HHS’s notice.[2][3][4] | Absence from a list is not a permission and not a prohibition. | FDA category lists FDA Category 2 page |
Mechano growth factor appears in two places on FDA’s lists: Category 3 for MGF and the withdrawn-nominations list for pegylated MGF (PEG-MGF).[2][3] This site has no entry for either. For the full HHS policy walk-through, including the ten conditions, read the HHS peptide policy explainer, and for the running record of rules and dates see the Atlas policy tracker.

Compounded, outsourced, approved and research-labeled
Four kinds of product get called “legal” or “illegal” in the same breath. They sit under different rules, and the HHS notice speaks to only one of them.
Swipe the table sideways to see every column.
| Feature | 503A pharmacy or physician compounding | 503B outsourcing facility | FDA-approved drug | “Research use only” sale |
|---|---|---|---|---|
| Who makes it | A state-licensed pharmacist or a physician, or a federal facility.[15] | A facility that registers with FDA as an outsourcing facility.[15][16] | The company holding the FDA approval. | A seller, often online, that labels the product for research.[12][14] |
| FDA review of the product | None before it is dispensed. FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed.[15] | Same: not FDA-approved.[15] | FDA approves the product and its label, as on the Wegovy, Zepbound and Egrifta labels.[22][23][21] | None. |
| Prescription | A patient-specific prescription is required under section 503A.[4] | May or may not obtain patient-specific prescriptions.[16] | Per the label and law. | No prescription process. |
| Manufacturing rules | Not subject to current good manufacturing practice (CGMP). State boards of pharmacy have primary day-to-day oversight, and FDA conducts surveillance and for-cause inspections.[15] | Subject to CGMP and primarily overseen by FDA, with risk-based inspections.[15] | Approved manufacturing and label. | No FDA oversight of the seller’s product quality. |
| Ingredient rules | Bulk substance needs a monograph, a place in an approved drug, or a place on the bulks list.[4][1] | Separate 503B rules; HHS’s October notice does not apply to 503B facilities.[4] | Not applicable. | Not applicable. |
| What the 2026 documents say | HHS’s draft policy covers this route for six peptides under ten conditions.[4] | Not covered by the October notice. GHRP-2, GHRP-6 and ipamorelin acetate are Category 2 for 503B.[4][3] | Approval is product-specific and does not extend to compounded copies.[12] | FDA’s August 24 letter said research labels did not change its conclusion that the products were intended for human use. HHS says its policy aims to discourage research-use-only peptides from foreign manufacturers.[14][4] |
The research-use-only column deserves one more paragraph, because it is the one with the most folklore. FDA’s regulation on intended use says the intent behind a product is judged objectively and can be shown by labeling claims, advertising, or oral or written statements.[17] In the August 24 letter FDA applied that to a seller’s web copy, describing studies of effects on conditions, and to the sale of bacteriostatic water alongside injectable peptides, and said the research-use-only labels did not change its conclusion.[14] HHS’s October notice is limited to compounding by pharmacies, federal facilities and physicians, and does not authorize research-labeled retail sales.[5][4] A genuine laboratory standard used in an assay is a different matter from a product marketed toward human use, and FDA’s test is the surrounding evidence, not the label.
For help reading what a purity certificate can and cannot show, see the guide to reading a peptide test report, and for why route matters see the guide to injected, oral and nasal routes. The Atlas explains what a 503A pharmacy is in plain terms.
State rules
The HHS notice is a federal statement about federal enforcement. A 503A pharmacy is licensed and inspected by its state board, which FDA describes as having primary day-to-day oversight, so what a given pharmacy may do also depends on its state.[15] Only two state documents could be read directly for this page.
- Louisiana: Act 374 (SB 253), signed May 22, 2026 and effective August 1, 2026, bars licensing boards from prohibiting a prescriber from providing peptides shipped from an FDA-registered 503B facility or a 503A pharmacy that meets the cited federal requirements. It also bars boards from prohibiting a Louisiana-licensed pharmacist from compounding and dispensing peptides, provided the pharmacist and pharmacy comply with section 503A and the applicable USP-NF chapters.[19] An earlier draft of the bill referred to FDA’s Category 2 list; the enrolled text and digest read for this page do not. The act ties its protection to federal compliance and does not itself make an unapproved peptide eligible.
- Alabama: the State Board of Pharmacy’s February 2026 newsletter says it met with the Attorney General’s office in January about a case involving peptides labeled “for research use only” used in humans, describes a gap for products bought directly from unlicensed companies, and says that gap needs legislative action. It is a statement of concern and not a rule.[20]
Secondary reports mention actions by other state boards and attorneys general. They are left out until a board, legislature or court document is found for each.
Sports and WADA
Federal compounding status does not decide anti-doping status. The World Anti-Doping Agency’s 2026 Prohibited List, in effect from 1 January 2026, names several of these peptides.[18]
- BPC-157 is named as an example in S0, the class for non-approved substances, which is prohibited at all times.[18]
- S2 names growth hormone fragments such as AOD-9604; releasing hormones including CJC-1295, sermorelin and tesamorelin; releasing peptides including hexarelin, GHRP-2 and GHRP-6; secretagogues including ibutamoren (MK-677) and ipamorelin; thymosin-beta-4 and its derivatives, for example TB-500; and mechano growth factors.[18]
- MOTS-c is named under S4 as an example of an AMPK activator.[18]
- GHK-Cu, melanotan, thymosin alpha-1, Semax, selank, epitalon and GLP-1 agents were not found by name in the 2026 text. Not being named is not clearance, because S0 is a catch-all for non-approved substances. Athletes need to check with their anti-doping organization.[18]
WADA published its 2027 list on 6 October 2026, effective 1 January 2027. The coverage read for this page mentions GLP-1 receptor agonists as unchanged and does not discuss other peptides, so check the list itself.[37]
What is still open
- The comment period on the HHS notice closes November 13, 2026. HHS says it may revisit or revise the policy, and the policy ends for each peptide when a final rule addresses it.[5][4]
- No proposed rule adding any peptide to the bulks list was found. The HHS notice says FDA’s future rulemakings may propose adding some or all of the six.[5] The regulation text current on 22 October 2026 still lists six non-peptide substances.[11] One law-firm commentary notes that only six substances have reached the list through notice-and-comment rulemaking since nominations began, so final action could take a long time.[33]
- Whether FDA follows its advisory committee or its own staff is open. The committee’s July recommendations contradict the staff briefing, and HHS adopted an enforcement approach instead of a rule.[8][4]
- Next committee meeting: before the end of February 2027, for GHK-Cu at minimum.[2]
- Oral and topical forms of BPC-157 and KPV carry an oral-bioavailability documentation condition that the notice does not define.[4]

Frequently asked questions
Is BPC-157 legal?
It depends which activity is meant, and the documents answer only part of it. BPC-157 is not FDA-approved and is not on the 503A bulks list. FDA removed it from Category 2 on April 22, 2026. On October 30, 2026 HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound BPC-157 acetate by subcutaneous, intramuscular, oral or topical routes under ten conditions. That is enforcement discretion, not approval, and each state’s pharmacy rules still apply to the pharmacy.[4][5][15]
Did FDA approve BPC-157?
No approval of BPC-157 for any use appears in the documents reviewed, and HHS’s notice refers to a lack of approved products for these peptides. Three events are often mistaken for approval: removal from Category 2 on April 22, 2026, the advisory committee’s July 2026 vote, and HHS’s October 2026 notice. FDA’s drug center recommended against listing BPC-157, and the committee vote is advice.[5][4]
What is the FDA Category 2 peptides list?
Category 2 is FDA’s interim label for nominated bulk substances that it says raise significant safety risks. In 2023 FDA placed a group of peptides there. On April 22, 2026 BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon and others came off after their nominators withdrew them. As of FDA pages checked on November 2, 2026, the 503A Category 2 list names six substances, including kisspeptin-10 and ibutamoren mesylate. GHRP-2, GHRP-6 and ipamorelin acetate are Category 2 for 503B outsourcing facilities.[2][3][4]
Which peptides can be compounded?
Federal law lets a 503A pharmacy compound only from bulk substances that have a monograph, are components of FDA-approved drugs, or are on the bulks list, and no peptide is on the list. Peptides that are components of approved drugs, such as semaglutide, tirzepatide, liraglutide and tesamorelin, can qualify under the approved-component test, with other restrictions and with compounded versions remaining unapproved. For six unapproved peptides, HHS’s draft policy says it will not enforce against qualifying compounders. FDA says retatrutide and cagrilintide cannot be used in compounding.[4][11][12]
What was the FDA peptide advisory committee vote?
On July 23 and 24, 2026 the Pharmacy Compounding Advisory Committee considered seven peptides. HHS’s policy records that it voted in favor of including BPC-157, epitalon, KPV, TB-500, Semax and MOTS-c, against its drug center’s recommendation. Trade press reports it did not recommend emideltide (DSIP). Vote tallies differ between news sources and FDA had not posted voting results when checked, so no counts are printed here. A committee vote is advice, not a rule.[4][6][29]
Can you buy peptides online legally?
FDA has stated its position on products sold online as research chemicals in its warning letters. In a letter dated August 24, 2026 it said research-use-only and not-for-human-consumption labels did not change its conclusion that the seller’s products were intended for human use. Its October 1, 2026 page urges consumers not to buy GLP-1 products sold that way. Compounded products come from licensed pharmacies and outsourcing facilities, and HHS’s draft policy addresses 503A compounding, not research-labeled retail sales. Whether a particular sale is lawful turns on facts this page cannot assess.[14][12][4]
What is the 503A bulks list, and is any peptide on it?
It is the list of bulk drug substances, in 21 CFR 216.23, that pharmacists and physicians may use when no monograph or approved-drug component applies. It names six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. None is a peptide. Adding a substance requires rulemaking.[11][1]
Does “research use only” make a peptide legal to sell?
FDA’s regulation says intended use is judged by objective evidence, including labeling claims, advertising and oral or written statements. In its August 24, 2026 warning letter FDA said research-use-only labels did not change its conclusion that a seller’s products were intended for human use. HHS’s October notice does not authorize research-labeled sales.[17][14][5]
Is compounded semaglutide or tirzepatide FDA-approved?
No. FDA states that compounded versions are not FDA-approved. Its October 1, 2026 page says it is not aware of a lawful basis for compounding with semaglutide sodium or semaglutide acetate salts. On February 6, 2026 FDA announced it intends to restrict GLP-1 active ingredients used in non-approved compounded drugs. The brand drugs Wegovy and Zepbound are approved.[12][13][22][23]
Are peptides banned in sports?
Several are. WADA’s 2026 Prohibited List names BPC-157 under S0, and TB-500, CJC-1295, sermorelin, tesamorelin, hexarelin, GHRP-2, GHRP-6, ibutamoren, ipamorelin and AOD-9604 under S2. MOTS-c is named under S4. Compounding status under FDA rules does not change this.[18]
Bottom line
The formal route for a peptide into pharmacy compounding, the 503A bulks list, still has no peptide on it.[11] What changed in 2026 sits around that list. FDA removed a group of peptides from its Category 2 safety list after their nominators withdrew the nominations, its advisory committee recommended six of seven over its own staff’s objection, and HHS published a draft, nonbinding policy covering six peptides in set forms, routes and conditions.[3][4][5] Peptides that are components of approved drugs follow a different path, and retatrutide and cagrilintide are outside it by FDA’s account.[12] What remains open is the comment period, a rule that has not been proposed, and a second committee meeting expected by the end of February 2027. This page documents status and does not tell anyone what to use.
Keep reading
Sources
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Page content current as of 14 May 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act Primary source: FDA page. Defines the three interim categories and the January 7, 2025 cutoff.
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Categories 1, 2 and 3). Updated 14 May 2026. https://www.fda.gov/media/94155/download Primary source: FDA list. Category 1, 2 and 3 membership and the GHK-Cu notes.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Primary source: FDA page. Current Category 2 entries (503A and 503B) and the list of nominations withdrawn from Category 2.
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B (PDF). October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Primary source: HHS policy document. The notice calls it a draft and not binding.
- Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice of availability, document 2026-22192, docket HHS-OASH-2026-0496. Filed for public inspection 28 October 2026. https://public-inspection.federalregister.gov/2026-22192.pdf Primary source: Federal Register public inspection copy. Comments due two weeks after publication.
- U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, July 23 to 24, 2026 (agenda, roster, briefing documents). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 Primary source: FDA advisory committee page. No minutes or voting results were posted when checked.
- Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. 91 FR 20465, document 2026-07361, published 16 April 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request Primary source: Federal Register meeting notice. Lists the seven substances and the uses evaluated.
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 2026: introduction. https://www.fda.gov/media/193342/download Primary source: FDA staff briefing. States FDA’s proposal not to include any of the 14 forms.
- U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024 (CJC-1295, AOD-9604, thymosin alpha-1). https://www.fda.gov/media/185642/download Primary source: FDA minutes.
- U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024 (ipamorelin, kisspeptin-10, ibutamoren, L-theanine). https://www.fda.gov/media/185412/download Primary source: FDA minutes.
- 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A. Electronic Code of Federal Regulations, current as of 22 October 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 Primary source: regulation. The final 503A bulks list.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 1 October 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Primary source: FDA page.
- U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. Press announcement, 6 February 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs Primary source: FDA press announcement.
- U.S. Food and Drug Administration. Warning letter to Peak Performance Peptides, reference 735127, dated 24 August 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026 Primary source: FDA warning letter.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Page content current as of 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers Primary source: FDA page.
- U.S. Food and Drug Administration. Questions and Answers Related to Guidance for Entities Considering Whether to Register as Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-related-guidance-entities-considering-whether-register-outsourcing-facilities Primary source: FDA page (content dated 2018).
- 21 CFR 201.128. Meaning of intended uses. Legal Information Institute copy. https://www.law.cornell.edu/cfr/text/21/201.128 Primary source: regulation.
- World Anti-Doping Agency. Prohibited List 2026 (in effect 1 January 2026), PDF copy hosted on segas.gr, a national athletics federation site. https://www.segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf Primary document read from a federation-hosted copy. Confirm against WADA’s own site.
- Louisiana Legislature. SB 253 of the 2026 Regular Session (peptides), Act 374: bill status, digest and enrolled text. https://www.legis.la.gov/legis/BillInfo.aspx?i=250428 Primary source: state legislature record. Signed 22 May 2026, effective 1 August 2026.
- Alabama State Board of Pharmacy. State newsletter, February 2026 (Vol. 42, No. 1), as hosted by NABP. https://nabp.pharmacy/wp-content/uploads/2026/02/February-2026-Alabama-State-Newsletter.pdf Primary source: state board newsletter. A statement of concern, not a rule.
- EGRIFTA WR (tesamorelin) for injection, prescribing information, revised 3/2025. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf Primary source: FDA-approved label.
- WEGOVY (semaglutide), prescribing information, revised 02/2026. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf Primary source: FDA-approved label. Initial U.S. approval 2017.
- ZEPBOUND (tirzepatide), prescribing information, revised 04/2026. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s050lbl.pdf Primary source: FDA-approved label. Initial U.S. approval 2022.
- SAXENDA (liraglutide), prescribing information, revised 10/2025, and VICTOZA (liraglutide), revised 05/2025. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s022lbl.pdf Primary source: FDA-approved labels. Initial U.S. approval 2010. Victoza label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s044lbl.pdf
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval for First Treatment for Barth Syndrome (Forzinity, elamipretide). Press announcement, 19 September 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome Primary source: FDA press announcement.
- U.S. Food and Drug Administration. NDA 210557 approval letter, Vyleesi (bremelanotide), 21 June 2019. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf Primary source: FDA approval letter.
- Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 78 FR 14095, 4 March 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams Primary source: Federal Register determination.
- McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. 2026. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/ Law-firm analysis, used as a pointer only. Its vote tallies are not reproduced here.
- Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list. 24 July 2026. https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html Trade press, used as a pointer only. Its tallies differ from other outlets on epitalon.
- American Journal of Managed Care. FDA Panel Backs 6 Peptides for Compounding. 31 July 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding Trade press, used as a pointer only.
- Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. 2026. https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/ Law-firm analysis, used as a pointer only. Source for the 15 April announcement date and the planned later review of five peptides.
- Frier Levitt. The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry. 2026. https://www.frierlevitt.com/articles/fda-peptide-regulation-rfk-announcement-compounding-pharmacies/ Law-firm analysis, used as a pointer only. Source for the 27 February 2026 remarks.
- FDA Law Blog (Hyman, Phelps & McNamara). The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion … Not the Finish Line. 28 October 2026. https://www.thefdalawblog.com/?p=16231 Law-firm commentary, used as a pointer only.
- Foley & Lardner. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. 30 October 2026. https://www.foley.com/?p=130749 Law-firm analysis, used as a pointer only. Source for the 13 November comment date.
- AFS Law. RUO-ined: Five Peptide Vendors Learn That ‘Research Use Only’ Is Not a Legal Strategy. 2026. https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy Law-firm analysis, used as a pointer only. Source for the count of five letters.
- Alliance for Pharmacy Compounding. Short Takes, 24 July 2026. https://a4pc.org/apc-short-takes/short-takes-july-24-2026 Trade-association newsletter, used as a pointer only (eight temporary committee members).
- World Rugby. WADA publishes 2027 Prohibited List. 2026. https://www.world.rugby/keep-rugby-clean/news/1048285/wada-publishes-2027-prohibited-list Sports-federation news item, used as a pointer only. Confirm against WADA.
- DLA Piper. FDA adcomm recommends adding six peptides to bulk list. 31 July 2026. https://www.dlapiper.com/insights/publications/2026/07/fda-adcomm-recommends-adding-six-peptides-to-bulk-list Law-firm analysis, used as a pointer only. Source for the planned review of five more peptides before February 2027.
Educational reference only, not legal or medical advice. This page describes what regulators and legislatures have written. It does not say which product anyone should use, and a peptide’s presence in a table is not a statement that it is safe, effective or suitable.